<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="116168">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02137668</url>
  </required_header>
  <id_info>
    <org_study_id>Davies 1</org_study_id>
    <nct_id>NCT02137668</nct_id>
  </id_info>
  <brief_title>Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin</brief_title>
  <official_title>The Human Gastrointestinal Tract Microbiota in the Setting of Treating Primary Sclerosing Cholangitis and Biliary Atresia With Vancomycin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sacramento Pediatric Gastroenterology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sacramento Pediatric Gastroenterology</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is twofold. First, is to determine whether vancomycin is effective
      in the early treatment of Biliary Atresia (BA) and Primary Sclerosing Cholangitis (PSC), and
      if so, by what mechanism. Secondly, to characterize human intestinal microbial communities
      and their interactions with the host.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2010</start_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Determine the benefit of oral vancomycin therapy for Primary Sclerosing Cholangitis and Biliary Atresia</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood tests, imaging studies and/or liver biopsy changes before and while on oral vancomycin will determine the benefit of the treatment.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Primary Sclerosing Cholangitis</condition>
  <condition>Biliary Atresia</condition>
  <arm_group>
    <arm_group_label>Oral Vancomycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Vancomycin</intervention_name>
    <arm_group_label>Oral Vancomycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Persons who have primary sclerosing cholangitis, biliary atresia, a chronic
             intestinal disorder or who are undergoing upper or lower endoscopy.

          -  Persons who have primary sclerosing cholangitis or biliary atresia who are good
             candidates for vancomycin therapy.

        Exclusion Criteria:

          -  Patients that have taken antibiotics and/or immunomodulators within the last 3 months
             will be excluded as this will alter the original bacterial flora.

          -  Females who are pregnant may not participate.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yinka Davies, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sacramento Pediatric Gastroenterology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sacramento Pediatric Gastroenterology</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95841</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yinka Davies, MD</last_name>
      <phone>916-332-1244</phone>
    </contact>
    <investigator>
      <last_name>Yinka Davies, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>May 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Biliary Atresia</mesh_term>
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
